ASCO21: Exploring the IMpower010 trial data, an interview with Charlie Fuchs

Written by Charlie Fuchs (Roche/Genentech)

IMpower010, immunotherapy, lung cancer, asco

Interim data from the IMpower010 trial has demonstrated that Tecentriq® (atezolizumab) following surgery and chemotherapy reduces the risk of disease-free survival by 34% in some patients with Stage II-IIIA NSCLC, compared with best supportive care. The data is pivotal as it is the first time that cancer immunotherapy has brought a clinically meaningful improvement to certain people with early lung cancer in the adjuvant setting. In this interview we speak with Charlie Fuchs (Roche, Switzerland and Genentech, CA, USA) about the importance of the data.  Can you give us an overview of the IMpower010 trial data? IMpower010 is a Phase...

To view this content, please register now for access

It's completely free